Biphasic Insulins

An insulin preparation that is designed to provide immediate and long term glycemic control in a single dosage. Biphasic insulin typically contains a mixture of REGULAR INSULIN or SHORT-ACTING INSULIN combined with a LONG-ACTING INSULIN.

Also Known As:

Networked: 197 relevant articles (18 outcomes, 83 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Shetty, Raman: 6 articles (11/2013 - 11/2013)
2.	Madsbad, Sten: 4 articles (01/2022 - 05/2002)
3.	Valentine, William J: 4 articles (12/2012 - 12/2005)
4.	Raskin, Philip: 4 articles (01/2011 - 05/2002)
5.	Lund, Søren S: 3 articles (01/2022 - 11/2009)
6.	Tarnow, Lise: 3 articles (01/2022 - 11/2009)
7.	Utsunomiya, Kazunori: 3 articles (09/2017 - 05/2008)
8.	Idris, I: 3 articles (05/2015 - 01/2014)
9.	Mamza, J: 3 articles (05/2015 - 01/2014)
10.	Home, Philip D: 3 articles (06/2014 - 05/2002)

Related Diseases

1.	Type 2 Diabetes Mellitus (MODY) 07/01/2011 - "Self-titrated biphasic insulin aspart 70/30 was found to be well-tolerated and effective in type 2 diabetes patients >65 years old, as well as in patients ≤65 years old. " 01/01/2007 - "Our goal was to review the current literature on the safety and efficacy of biphasic insulin aspart in type 1 and type 2 diabetes. " 01/01/2005 - "Efficacy of biphasic insulin aspart in patients with type 2 diabetes." 11/01/2013 - "Clinical experience with biphasic insulin aspart in people with type 2 diabetes: Results from the Libya cohort of the A1chieve study." 07/01/2012 - "Efficacy and safety of biphasic insulin aspart 70/30 in type 2 diabetes patients of different race or ethnicity (INITIATEplus trial)."
2.	Weight Gain 12/01/2015 - "No difference was observed between the basal plus and the biphasic insulin groups in responders (HbA1c <7%, 20.6 vs 27.9%; p = 0.12), weight gain (2.06 vs 2.50 kg; p = 0.2), diabetes-specific quality of life (Audit of Diabetes-Dependent Quality of Life average weighted impact (AWI) score) and generic health status (five-dimension European Quality of Life questionnaire). " 04/01/2011 - "The overall incidence of hypoglycaemia ranged from 0 to 4.71 events/patient/30 days; weight gain ranged from 1.75 kg for basal to 3 kg for biphasic insulin. " 02/01/2007 - "Treatment with biphasic insulin aspart was associated with weight gain and lower risk of adverse gastrointestinal events. " 06/01/2008 - "Adjunctive prandial or biphasic insulin for type 2 diabetes improved glycaemic control but increased hypoglycaemia and weight gain." 02/01/2011 - "Compared with biphasic insulin, the basal-bolus regimen was associated with a greater chance to reach the HbA(1c) goal (odds ratio 1.75 [95% CI 1.11-2.77]), with no greater hypoglycemia or weight gain. "
3.	Hypoglycemia (Reactive Hypoglycemia) 12/01/2011 - "Administration of 70/30 biphasic insulin 3 times daily is a safe therapeutic regimen in diabetic patients on continuous EN as it maintains glycemia in the target range and might produce fewer episodes of hypoglycemia." 07/11/1970 - "Insulin mixtures and hypoglycemia." 06/01/2011 - "NPH and NPH-based insulin mixtures no longer have a place in the treatment of T1DM because of their early peak effects and relatively short duration of action, which result into risk of nocturnal hypoglycemia and fasting hyperglycemia, respectively, after the evening injection. " 02/01/2011 - "Compared with biphasic insulin, the basal-bolus regimen was associated with a greater chance to reach the HbA(1c) goal (odds ratio 1.75 [95% CI 1.11-2.77]), with no greater hypoglycemia or weight gain. " 01/01/2007 - "The risk of hypoglycemia is similar to or less than that seen with other biphasic insulins or NPH insulin. "
4.	Hyperthyroidism 10/01/1976 - "Pretreatment with either glucose or xylitol almost completely restored the biphasic insulin response to arginine in patients with hyperthyroidism, whereas pretreatment with aminophylline only partially improved the insulin response. "
5.	Hyperlipidemias (Hyperlipidemia) 03/01/2005 - "Biphasic insulin aspart compared to biphasic human insulin reduces postprandial hyperlipidemia in patients with Type 2 diabetes." 03/01/2005 - "Compared to conventional human premixed insulin the prandial therapy with biphasic insulin aspart results not only in an improvement of glucose tolerance but also in a significant reduction of postprandial hyperlipemia."

Related Drugs and Biologics

1.	Insulin (Novolin)
2.	Glucose (Dextrose)
3.	insulin aspart protamine drug combination 30:70 insulin aspart
4.	Insulin Lispro (Humalog)
5.	Hypoglycemic Agents (Hypoglycemics)
6.	Metformin (Glucophage)
7.	biphasic human insulin 30
8.	Insulin Aspart (NovoLog)
9.	Insulin Detemir (Levemir)
10.	Insulin Glargine (Lantus)

Related Therapies and Procedures

1.	Glycemic Control
2.	Therapeutics
3.	Injections
4.	Stents
5.	Drug-Eluting Stents